AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

TNYA · NASDAQ · Biotechnology

Tenaya Therapeutics

Develops gene therapies and small molecules for genetically defined heart diseases.

$0.6956

After-hours close+0.00 (+0.40%)

At close$0.6928(−0.35%)

Something off on this page? Send us feedback.

Profile

Tenaya Therapeutics, Inc.TNYAHealth Care

Develops gene therapies and a targeted small-molecule candidate for genetically defined heart diseases. Its pipeline includes TN-201 and TN-401 gene therapies and TN-301, an HDAC6 inhibitor, with development centered on clinical studies rather than commercial products.

Develops gene therapies and a targeted small-molecule candidate for genetically defined heart diseases. TN-201 is for MYBPC3-associated hypertrophic cardiomyopathy, while TN-401 is for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. TN-301 is an HDAC6 inhibitor for heart failure with preserved ejection fraction and selected rare cardio-metabolic indications.

Based in South San Francisco, California, the clinical-development organization uses internal discovery and AAV gene-therapy capabilities. TN-201 and TN-401 are in Phase 1b/2 trials, with clinical execution shaping the path from data generation to regulatory discussions.

Development priorities have concentrated resources on data from the MyPEAK-1 and RIDGE-1 trials.

Company facts

CEOFaraz Ali

ListedJul 30, 2021

ExchangeNASDAQ

HeadquartersSouth San Francisco, CA

CountryUnited States

Employees70

CIK0001858848

ISINUS87990A1060

Key statistics

Market cap$149.8M

EPS (ttm)−$0.5300

P/E (ttm)−1.30

ROE-108.0%

P/B2.16

P/S112.17

Dividend yield—

Beta2.37vs XLV 0.04

Year to date −5.1% · Average volume (30d) 1.9M

Analysts

Price target, next 12 months$2.00+189.9%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy6 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $0.6900

High$2.00+189.9%

Median$2.00+189.9%

Low$2.00+189.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
Mar 12, 2026	Leerink Partners	Target	$2
Jan 8, 2026	Morgan Stanley	Target	$2
Dec 12, 2025	H.C. Wainwright	Target	$3

Earnings

EPS

Estimate−$0.11

ReportedDue Nov 11, 2026

Revenue

Estimate$802.5K

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 5, 2026Q2 FY26	−$0.07	−$0.20	−192.7%	$10.0M	$1.1M	−88.9%	−7.51%
May 6, 2026Q1 FY26	−$0.09	−$0.09	0.0%	$7.5M	$225.0K	−97.0%	+7.37%
Mar 11, 2026Q4 FY25	−$0.13	−$0.12	+7.7%	$3.0M	—	—	+3.98%
Nov 10, 2025Q3 FY25	−$0.15	−$0.12	+20.0%	—	—	—	−0.70%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$225.0K	$1.1M
Gross profit	$0	−$2.1M	$0	$3.9M	−$1.5M	$1.1M
Operating income	−$27.5M	−$24.1M	−$20.9M	−$20.8M	−$20.1M	−$44.1M
Net income	−$26.9M	−$23.3M	−$20.3M	−$20.2M	−$19.3M	−$43.4M
Diluted EPS	−$0.24	−$0.14	−$0.12	−$0.12	−$0.09	−$0.20
Gross margin	—	—	—	—	-683.6%	100.0%
Operating margin	—	—	—	—	-8,917.8%	-3,971.9%

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $78.1M · Total debt $3.9M · Total assets $93.5M · Shareholders' equity $69.4M

Dividends

No dividends on record.

Ownership

Institutions 25.03%54.31M sharesInsiders 23.07%50.06M sharesOther 51.90%112.63M shares

Shares outstanding 217.00M · Float —

Float — provider float is below the insider stake.

The provider's float is smaller than the insider stake it should exclude, so it is not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
TCG Opportunity III GP, LLC	49.31M	23.10%	13D	Feb 26, 2026
David V. Goeddel · director, 10 percent owner:	49.31M	22.73%	Form 4	Mar 7, 2025
Integrated Core Strategies (US) LLC	11.58M	5.20%	13G	Aug 24, 2026
Vanguard Capital Management LLC	8.48M	3.91%	13F	May 15, 2026
Millennium Management LLC	5.46M	2.51%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 17, 2026	Whittemore Tingley	officer: Chief Medical Officer	−5,787	$0.7098
Aug 17, 2026	Faraz Ali	director, officer: Chief Executive Officer	−22,232	$0.7097
May 18, 2026	Tomohiro Higa	officer: SVP, Finance	−1,485	$0.7932
May 18, 2026	Whittemore Tingley	officer: Chief Medical Officer	−3,121	$0.7936
May 18, 2026	Faraz Ali	director, officer: Chief Executive Officer	−3,390	$0.7934